Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy

Bayona A, Benavent P, Muriel A, et al. Outcomes of repeat fine needle aspiration biopsy for AUS/FLUS thyroid nodules. Eur J Endocrinol.

;185(4):497-506. https://pubmed.ncbi.nlm.nih.gov/34313606. https://doi.org/10.1530/EJE-21-0330.

Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than

repeat fine-needle aspiration in thyroid nodules read as nondiagnostic

or atypia of undetermined significance by the Bethesda system for

reporting thyroid cytopathology. Thyroid. 2012;22(5):468-75. https://pubmed.ncbi.nlm.nih.gov/22304417. https://doi.org/10.1089/thy.2011.0185.

Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159-65. https://pubmed.ncbi.nlm.nih.gov/19888858. https://doi.org/10.1089/thy.2009.0274.

American Thyroid Association Guidelines Taskforce on Thyroid

Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM,

Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated

thyroid cancer. Thyroid. 2009;19(11):1167–114. https://pubmed.ncbi.nlm.nih.gov/19860577.

https://doi.org/10.1089/thy.2009.0110.

Gharib H, Papini E, Paschke R, et al. American Association of Clinical

Endocrinologists, Associazione Medici Endocrinologi, and European

Thyroid Association Medical guidelines for clinical practice for the

diagnosis and management of thyroid nodules: Executive summary

of recommendations. endocrine practice. 2010;16(3):468–75. https://pubmed.ncbi.nlm.nih.gov/20551008. https://doi.org/10.4158/EP.16.3.468.

Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid

nodules classified as Bethesda category III (AUS/FLUS). Thyroid.

;24(5):832–9. https://pubmed.ncbi.nlm.nih.gov/24341462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948206. https://doi.org/10.1089/thy.2013.0317.

Gweon HM, Son EJ, Youk JH, Kim JA. Thyroid nodules with Bethesda

system III cytology: Can ultrasonography guide the next step?

Ann Surg Oncol. 2013;20(9):3083–8. https://pubmed.ncbi.nlm.nih.gov/23700214. https://doi.org/10.1245/s10434-013-2990-x.

Yoo WS, Choi HS, Cho SW, et al. The role of ultrasound findings in

the management of thyroid nodules with atypia or follicular lesions

of undetermined significance. Clin Endocrinol (Oxf). 2014;80(5):735–42. https://pubmed.ncbi.nlm.nih.gov/24117478. https://doi.org/10.1111/cen.12348.

Mehta RS, Carty SE, Ohori NP, et al. Nodule size is an independent

predictor of malignancy in mutation-negative nodules with follicular

lesion of undetermined significance cytology. Surgery. 2013;154(4):

–6. https://pubmed.ncbi.nlm.nih.gov/24074409. https://doi.org/10.1016/j.surg.2013.05.015

Carr R, Ustun B, Chhieng D, et al. Radiologic and clinical predictors

of malignancy in the follicular lesion of undetermined significance

of the thyroid. Endocr Pathol. 2013;24(2):62–8. https://pubmed.ncbi.nlm.nih.gov/23595630.

https://doi.org/10.1007/s12022-013-9240-4.

Rosario PW. Thyroid nodules with atypia or follicular lesions of

undetermined significance (Bethesda Category III): Importance of

ultrasonography and cytological subcategory. Thyroid. 2014;24(7):

–20. https://pubmed.ncbi.nlm.nih.gov/24684285. https://doi.org/10.1089/thy.2013.0650.

Ogmen BE, Aydin B, Kilinc I, Altinboga, AA, Ersoy R, Cakir B. Can

repeat biopsies change the prognoses of AUS/FLUS nodule? Eur

Thyroid. 2020;9(2):92-8. https://pubmed.ncbi.nlm.nih.gov/32257958. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109390. https://doi.org/10.1159/000504705.

Broome JT, Cate F, Solorzano CC. Utilization and impact of repeat

biopsy for follicular lesion/atypia of undetermined significance. World

J Surg. 2014;38(3): 628–33. https://pubmed.ncbi.nlm.nih.gov/24233659. https://doi.org/10.1007/s00268-013-2330-0.

VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia

of undetermined significance in thyroid fine-needle aspirations:

Should repeated fna be the preferred initial approach? Am J Clin

Pathol. 2011;135(5):770–5. https://pubmed.ncbi.nlm.nih.gov/21502433. https://doi.org/10.1309/AJCP4P2GCCDNHFMY.

Hong SH, Lee H, Cho MS, Lee JE, Sung YA, Hong YS. Malignancy risk

and related factors of atypia of undetermined significance/follicular

lesion of undetermined significance in thyroid fine needle aspiration.

Int J Endocrinol. 2018;2018:4521984. https://pubmed.ncbi.nlm.nih.gov/30154840. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091291. https://doi.org/10.1155/2018/4521984.

Wong LQ, LiVolsi VA, Baloch ZW. Diagnosis of atypia/follicular lesion

of undetermined significance: An institutional experience. Cytojournal.

;11(1):23. https://pubmed.ncbi.nlm.nih.gov/25210530. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158655. https://doi.org/10.4103/1742-6413.139725.

Kim DS, Kim DW, Heo YJ, et al. Utility of including BRAF mutation analysis with ultrasonographic and cytological diagnoses in ultrasonography-guided fine-needle aspiration of thyroid nodules. PLoS ONE. 2018;13(8):e0202687. https://pubmed.ncbi.nlm.nih.gov/30118506. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097667. https://doi.org/10.1371/journal.pone.0202687.

Burch HB, Burman KD, Cooper DS, Hennessey JV, Vietor NO. A 2015

Survey of clinical practice patterns in the management of thyroid

nodules. J Clin Endocrinol Metab. 2016;101(7):2853-62. https://pubmed.ncbi.nlm.nih.gov/27014951.

https://doi.org/10.1210/jc.2016-1155.

Stewardson P, Eszlinger M, Paschke R. Diagnosis of endocrine disease: Usefulness of genetic testing of fine-needle aspirations for diagnosis of thyroid cancer. Eur J Endocrinol. 2022;187(3):R41-52. https://pubmed.ncbi.nlm.nih.gov/35900312. https://doi.org/10.1530/EJE-21-1293.

Nicholson KJ, Roberts MS, McCoy KL, Carty SE, Yip L. Molecular

testing versus diagnostic lobectomy in Bethesda III/IV thyroid nodules:

A cost-effectiveness analysis. Thyroid. 2019;29(9):1237-43. https://pubmed.ncbi.nlm.nih.gov/31407625. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366255. https://doi.org/10.1089/thy.2018.0779.

Elomami A, Elhag SA, Alseddeeqi E. Cytological sub-classification

of atypia of undetermined significance may predict malignancy risk

in thyroid nodules. Acta Cytol. 2012;65(3):205-12. https://pubmed.ncbi.nlm.nih.gov/33524971.

https://doi.org/10.1159/000513066.

Chen JC, Pace SC, Chen BA, Khiyami A, McHenry CR. Yield of repeat

fine-needle aspiration biopsy and rate of malignancy in patients

with atypia or follicular lesion of undetermined significance: The

impact of the Bethesda System for reporting thyroid cytopathology.

Surgery. 2012;152(6):1037-44. https://pubmed.ncbi.nlm.nih.gov/23040711. https://doi.org/10.1016/j.surg.2012.08.052.

Abelardo AD, Sotalbo K. Clinical management of thyroid aspirates diagnosed as atypia of undetermined significance in the

Philippines. Gland Surg. 2020;9(5):1788-96. https://pubmed.ncbi.nlm.nih.gov/33224855. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667114. https://doi.org/10.21037/gs-20-426

Yoo MR, Gweon HM, Park AY, et al. Repeat diagnoses of Bethesda

Category III thyroid nodules: What to do next? PLoS One. 2015;10(6):e0130138. https://pubmed.ncbi.nlm.nih.gov/26115096. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482684. https://doi.org/10.1371/journal.pone.0130138.

Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists’ classification system. Am J Clin Pathol. 2011;135(6):852-9. https://pubmed.ncbi.nlm.nih.gov/21571958. https://doi.org/10.1309/AJCPZ33MVMGZKEWU.

Park JH, Kim HK, Kang SW, et al. Second opinion in thyroid fine-needle aspiration biopsy by the Bethesda system. Endocr J. 2012;59(3):205-12. https://pubmed.ncbi.nlm.nih.gov/22156326. https://doi.org/10.1507/endocrj.ej11-0274.

Mileva M, Stoilovska B, Jovanovska A, et al. Thyroid cancer detection

rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III. Radiol Oncol. 2018;52(4):370–6.

https://pubmed.ncbi.nlm.nih.gov/30265655. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287180. https://doi.org/10.2478/raon-2018-0039.

Cibas ES, Ali SZ. The 2017 Bethesda System for reporting thyroid

cytopathology. Thyroid. 2017;27(11):1341-6. Phttps://pubmed.ncbi.nlm.nih.gov/29091573. https://doi.org/10.1089/thy.2017.0500.

Gan TR, Nga ME, Lum JH, et al. Thyroid cytology-nuclear versus

architectural atypia within the “Atypia of undetermined significance/

follicular lesion of undetermined significance” Bethesda category

have significantly different rates of malignancy. Cancer Cytopathol.

;125(4):245–56. https://pubmed.ncbi.nlm.nih.gov/28192631. https://doi.org/10.1002/cncy.21823.

Ahn SH, Kim SD, Jeong WJ. Comparison of risk of malignancy in

a subgroup with atypia of undetermined significance/follicular